A recent study from Mass General Brigham indicates that varenicline, a smoking cessation medication, enhances the likelihood of quitting vaping among teens and young adults. Participants aged 16 to 25 who took varenicline had more than three times higher success rates compared to those receiving only behavioral counseling. Given the rising rates of vaping among youth, this study underscores the necessity for effective treatment options. Varenicline, while approved for adults, can now also be prescribed for individuals aged 16 to 25, providing a structured option to combat nicotine addiction in younger populations.
"Vaping is extremely popular among kids, and we know that this early nicotine exposure can make drugs like cocaine more addictive down the line, yet ours is the first treatment study to look at this vulnerable population."
"We wanted to help teens and young adults quit, and we found that prescribing varenicline is the best way to do that."
Collection
[
|
...
]